ArticleBritish journal of cancer2026
Urothelium marker UPK2 identifies aggressive colorectal cancers with distinct molecular and histological features.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundUroplakin-2 (UPK2) is a relatively specific marker for urothelial cancer, often used in the differential diagnosis of tumors of unknown origin. UPK2 expression has been observed in colorectal cancers (CRCs), prompting further investigation.
methodsUPK2 expression was analyzed in two independent CRC cohorts (N = 1851) and The Cancer Genome Atlas (N = 467). We investigated the histopathological, immunological, molecular, and clinical characteristics of UPK2-positive CRCs.
resultsUPK2 was expressed in 12% of CRCs and associated with adverse features including advanced stage, lymphovascular invasion, tumor budding, and micropapillary growth (p < 0.01). UPK2 positivity correlated with higher CRC-specific mortality in both cohorts (Cohort 1: HR 1.97, 95% CI 1.00-3.88; Cohort 2: HR 3.33, 95% CI 2.15-5.16). In the larger cohort, this association remained independent of other prognostic parameters (HR 2.31, 95% CI 1.46-3.65). UPK2-positive tumors showed reduced infiltration of CD3 + T cells, B cells, plasma cells, and M2-like macrophages. Molecularly, these tumors were associated with TP53 mutation, CMS4 subtype, and upregulation of genes linked to keratinization and squamous differentiation, such as KRT17 and DSG3 (p < 0.01).
conclusionsUPK2 marks a distinct subset of CRCs with poor prognosis, epithelial-mesenchymal transition, micropapillary growth, and squamous differentiation. These findings may affect the development of targeted therapies in precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.